Boothwyn Pharmacy LLC issued a nationwide recall of 186 vials of Semaglutide 2.5 mg/mL injection, 0.8 mL, on July 9, 2025. The FDA enforcement report classifies the recall as Class II with a high hazard level. Consumers and healthcare providers should stop using the product immediately and follow guidance from Boothwyn Pharmacy or a healthcare provider.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Semaglutide is a prescription GLP-1 receptor agonist used for glycemic control in type 2 diabetes and obesity management.
Subpotent drug may lead to reduced efficacy, potential poor disease management, and need for medical reassessment.
This recall is not part of a broader industry pattern.
Consumers and healthcare providers must halt use and await guidance; potential impact includes treatment disruption and need for alternative therapies.
FDA recall page D-0608-2025 for Boothwyn Pharmacy enforcement notice
Refund or replacement details to be issued by Boothwyn Pharmacy as recall progresses
Keep recall notification, packaging, receipts, and correspondence as records
Model numbers: 03202025@9 BUD 07/18/2025. Quantity: 186 vials. Distribution: U.S. nationwide. Sold by Boothwyn Pharmacy. Recall date: 2025-07-09. Status: ACTIVE.
No specific injuries or incidents are listed in the provided data.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Boothwyn Pharmacy recalls 642 vials of semaglutide 2.5 mg/mL injection sold nationwide in the U.S. The recall cites subpotent drug with Class II designation. Consumers and healthcare providers should stop using the product immediately and contact Boothwyn Pharmacy for guidance.
Boothwyn Pharmacy recalls 8 vials of Fluorescein 2% Ophth 3 mL nationwide after a subpotent drug finding. The recall was issued July 9, 2025 and remains active.
Boothwyn Pharmacy recalls 648 vials of semaglutide 2.5 mg/mL injection nationwide after detecting subpotent potency. The recall involves products distributed across the U.S. and is classified as Class II with a high hazard level. Stop using the product and contact Boothwyn Pharmacy or a healthcare provider for guidance.